VSIR and cancer: In cancer patients, VISTA is also a potential mediator of resistance to anti-CTLA-4 and anti-PD(L)1 therapies, where its overexpression has been associated with patients’ relapses (16, 17), making VISTA an attractive target for combination with other anti-cancer immunotherapies.